TRA2B

Across TCGA pan-cancer cohorts, TRA2B mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TRA2B’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TRA2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRA2B is over-expressed in tumor.

HNSC, COAD, and LSCC are the cancer types where TRA2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRA2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+0.343	<.001	11	view →
COAD	Male	III,IV	+0.691	<.001	9	view →
LSCC	Male	II,III,IV	+0.577	<.001	9	view →
LUAD	Male	All	+0.398	<.001	9	view →
PDAC	Male	All	+0.665	<.001	6	view →
CCRCC	Male	All	+0.055	.024	3	view →
OV	All	All	+1.014	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TRA2B–HNSC

Open the HNSC breakdown →